Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Breast Cancer Research : BCR|August 21, 2004
Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?Cindy A Wilson, Judy DeringBreast Cancer Research and Treatment|February 3, 2007
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitroRichard S Finn, Judy Dering, Charles Ginther, et al.Genes, Chromosomes & Cancer|March 25, 2011
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECKMarlena S Fejzo, Chuck Ginther, Judy Dering, et al.Genes, Chromosomes & Cancer|July 11, 2008
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification targetMarlena S Fejzo, Judy Dering, Chuck Ginther, et al.Breast Cancer Research and Treatment|November 17, 2009
Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancerBrenda Cohen, Mamiko Shimizu, Julia Izrailit, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2013
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.Plos One|May 5, 2021
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapyJason J Zoeller, Michael F Press, Laura M Selfors, et al.Gynecologic Oncology|December 26, 2013
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancerBeth Y Karlan, Judy Dering, Christine Walsh, et al.Gynecologic Oncology|August 7, 2010
Periostin promotes ovarian cancer angiogenesis and metastasisMin Zhu, Marlena S Fejzo, Lee Anderson, et al.Pageof 3